- British Biotechnology has reported the development of a breakthrough drug, lexipafant, for the treatment of acute pancreatitis. The company said that preliminary results showed that the drug was effective in improving the condition of the patient and inflammation of the pancreas, and if fully developed could exploit a market worth an estimated L300 million ($466.4 million). Shares in the company rose 6p to 461p following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze